Top Industry News

In a move to bolster its life-sciences business, Merck KGaA has agreed to acquire Bio-Techne, a Minneapolis-Minnesota provider of life-science tools, analytical technologies, and consumables, for $11.3 billion. The acquisition is one of…

To boost its portfolio in inflammatory and immunological therapeutics, AbbVie has agreed to acquire Apogee Therapeutics, a Waltham, Massachusetts-based clinical-stage bio/pharmaceutical company, for $10.9 billion.  Apogee’s lead assets are zumilokibart, a subcutaneous half-life extended monoclonal antibody for treating atopic dermatitis (eczema) in Phase…

Sanofi has named Paulo Fontoura, MD, PhD, an ex-Roche executive and currently Chief Medical Officer at Xaira Therapeutics, a South San Francisco, California-based company focused on applying AI and machine learning in drug discovery and development, as Executive Vice President,…

The latest from CDMOs, CMOs, and suppliers featuring Siegfried, Evonik, Aurobindo, Alcami, Sartorius, SK pharmteco, Shilpa Biologicals, Minaris, Argonaut Manufacturing Services, and Ensera.   Chemicals/Chemical API Manufacturing * Siegfried Opens Large-Scale API Facility* Evonik Divests Select Pharma Ingredient Production…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Eli Lilly and Company, Novartis, Otsuka, SK Biopharmaceuticals, and Stada. Highlights below.    For the latest news roundup on small and Emerging Pharma companies,…

The latest from small and Emerging Pharma companies featuring Campfield Therapeutics, Ollin Biosciences, RQ Bio, Sangamo Therapeutics, Serapha Bio, Boundless Bio, and Vedana Therapeutics.   For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * Campfield…

Johnson & Johnson (J&J) is investing $1 billion in its MedTech business through an expansion of manufacturing, packaging, and distribution capabilities at its facility in Jacksonville, Florida, for its Acuvue contact lenses. The company’s MedTech business focuses on surgical, cardiovascular, orthopedic, and…

Chiesi Group, a Parma, Italy-based bio/pharmaceutical company, has completed its $1.9-billion acquisition of KalVista Pharmaceuticals, a Framingham, Massachusetts-based commercial-stage bio/pharmaceutical company. The companies had announced the acquisition in April (April 2026).   KalVista’s lead product is Ekterly (sebetralstat) for treating hereditary angioedema…

The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s pharmaceutical regulatory authority, have announced a new liaison program to establish dedicated, reciprocal liaison officer roles…

As part of US drug-pricing reforms, a new proposal from the US Centers for Medicare & Medicaid Services (CMS) would establish a permanent framework for the Medicare Drug Price Negotiation Program by…